PRESS RELEASE Immunocore to present at upcoming investor conferences (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR)
Fireside Chat: Wednesday, June 9, 2021 at 10:30 am ET
The investor conferences will each be held in a virtual format and a live webcast of each fireside chat can be accessed in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. For conferences that offer replays, presentations will be made available for a limited time.
##
About Immunocore
Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most ad
Immunocore Holdings Limited: Immunocore Reports First Quarter 2021 Financial Results
Launched includes
$287 million in net proceeds from initial public offering and concurrent private placement in February 2021
Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced its results for the quarter ended March 31, 2021.
Highlights for the quarter included the presentation of the Phase 3 randomized data from the Company s lead candidate tebentafusp in the plenary clinical trial session at the American Association for Cancer Research (AACR) Annual Meeting, the launch of a global early access program for tebentafusp, and the successful completion of the Company s initial public offering resulting in net proceeds of $287 million.
Immunocore presents phase 3 data comparing tebentafusp with investigator s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting | Comunicados | Edición USA efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.